Indication: B-Acute Lymphoblastic Leukemia (B-ALL)

A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518, IND#133494) in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)

Sub-indication: B-Acute Lymphoblastic Leukemia (B-ALL)

Drug Study

Principal Investigator: Ashok Raj, M.D.
Norton Children's Cancer Institute, affiliated with the UofL School of Medicine

Sponsor: Children's Oncology Group (COG)

Search our entire site.